Tag Archive for bond restructuring

LR Health & Beauty Announces New Financing Structure

LR Health & Beauty SE lays foundation for positive future business performance with new financing structure. 

Company receives EUR 20 million of new capital and significantly reduces debt
Sustainable financing structure creates basis to implement targeted strategic measures to consistently drive LR’s success story

LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has today taken an important step to realign its financing structure. An agreement was reached with significant investors in the Company concerning a comprehensive restructuring of its 2024/2028 Bond (ISIN: NO0013149658) (the “Bond”) and the Company’s capital structure. This agreement provides for an aggregate injection of fresh capital of EUR 20 million. At the same time, the Company’s debt structure is being significantly reduced and restructured.
Jörg Körfer, Chief Executive Officer of LR Health & Beauty SE, comments:

“With this agreement on a realignment of our financing structure, we have reached an important milestone to reposition the LR Group to make it viable for the future. On the basis of a solid financing structure, we aim to initiate targeted strategic measures to now bring the LR Group onto a successful trajectory. The consistent digitalisation of our business processes, a focused further development of our

Read more...

LR Health & Beauty SE Reports FY2025 Results, Plans Bond Restructuring

LR Health & Beauty SE: Preliminary Results For Financial Year 2025, Target Equity Contribution, and Targeted Restructuring of the 2024/2028 Bonds. 
Ahlen, Germany – Based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) now expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million).
Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.

Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the

Read more...